Shots:

• The approval is based on results from four clinical trials- including three P-III trials and one P-II trial- that demonstrated significant improvements in both the signs and symptoms of dry eye disease
• The approval has made Eysuvis- the 1^st ocular corticosteroid for the treatment of dry eye disease and the 1^st drug approved specifically for the short-term (up to 2 wks.) treatment of the signs and symptoms of dry eye disease
• Eysuvis utilizes Kala’s Ampplify mucus-penetrating particle (MPP) drug delivery technology to enhance penetration of loteprednol etabonate into target tissue on the ocular surface. The company plans to launch Eysuvis in the US by the end of the year 2020

­ Ref: PRNewswire | Image: Kala Pharmaceuticals